Positive CHMP opinion for glaucoma drops

Article

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension (Simbrinza, Alcon) to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A child looks at the camera. She has on red glasses. Image credit: ©Annashou – stock.adobe.com

A new home treatment for amblyopia

Lynda Charters;Reviewed by Tamara Wygnanski-Jaffe, MD; and Nicholas Sala, DO
February 4th 2025
Article

Binocular eye tracking could serve as alternative to patching and provide visual acuity gains with heightened adherence rates

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A man wearing Nuance Audio hearing aid glasses speaks to a friend. Image courtesy of EssilorLuxottica

Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval

Emily Kaiser Maharjan
February 4th 2025
Article

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

An illustrated eyeball inside a DNA helix. Image credit: ©Adisak – stock.adobe.com

Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy

Grace Koennecke
February 3rd 2025
Article

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

An illustration of a genetic DNA helix with a red target on it. ©Елена Бутусова – stock.adobe.com

Viralgen and Axovia Therapeutics enter partnership, target retinal dystrophy in Bardet-Biedl Syndrome

Grace Koennecke
January 31st 2025
Article

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

© 2025 MJH Life Sciences

All rights reserved.